cardiomyopathy: A disease of the heart muscle or myocardium proper. Cardiomyopathies may be classified as either primary or secondary, on the basis of etiology, or on the pathophysiology of the lesion: hypertrophic, dilated, or restrictive.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
224 |
4. Check minimum number of eventsNone |
224 |
5. Include endpointsNone |
224 |
6. Filter based on genotype QC (FinnGen only) |
224 |
Control definitions (FinnGen only)
- Control exclude
- I9_OTHHEART
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Cardiomyopathies, Secondary/extrinsic
based on the number of shared cases.
Similar with more cases:
- Cardiomyopathy (excluding other)
- Cardiomyopathy
- Other heart diseases
- Other heart diseases, wide
- Cardiovascular diseases (excluding rheumatic etc)
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4781 | 746 | 3926 |
| Only index persons | 2094 | 381 | 1713 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.10 | 0.02 | 0.11 |
| Only index persons | 0.06 | 0.01 | 0.07 |
| Median age at first event (years) | |||
| Whole population | 56.51 | 59.10 | 55.87 |
| Only index persons | 58.60 | 60.45 | 58.19 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 224 | 65 | 159 |
| Unadjusted period prevalence (%) | 0.06 | 0.02 | 0.07 |
| Median age at first event (years) | 60.19 | 55.59 | 62.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 200
- Matched controls
- 1998
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
I42.6
ICD-10 Finland
Alcoholic cardiomyopathy
+∞
156.5
129
*
I50.9
ICD-10 Finland
Heart failure, unspecified
319.7
94.4
89
5
I42.0
ICD-10 Finland
Dilated cardiomyopathy
+∞
88.2
78
*
201
Kela drug reimbursment
Chronic cardiac insufficiency
119.6
77.2
80
11
I42.7
ICD-10 Finland
Cardiomyopathy due to drugs and other external agents
+∞
71.1
64
*
I48
ICD-10 Finland
Atrial fibrillation and flutter
69.3
58.7
66
14
I50.1
ICD-10 Finland
Left ventricular failure
+∞
54.7
50
*
I50.0
ICD-10 Finland
Congestive heart failure
330.4
51.6
50
*
C01AA05
ATC
digoxin; systemic
55.0
50.4
59
15
C03CA01
ATC
furosemide; systemic
10.9
49.0
118
233
C03DA01
ATC
spironolactone; oral
18.4
46.0
75
63
I42.9
ICD-10 Finland
Cardiomyopathy, unspecified
+∞
43.3
40
*
207
Kela drug reimbursment
Chronic arrhythmias
460.1
39.5
38
*
XFP20
NOMESCO Finland
Check up of cardiac pacemaker
112.7
35.0
37
*
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
9.7
31.3
70
105
B01AA03
ATC
warfarin; systemic
9.6
29.7
66
97
C07AB07
ATC
bisoprolol; oral
5.7
29.3
127
466
Z95.0
ICD-10 Finland
Presence of electronic cardiac devices
+∞
27.7
26
*
I47.2
ICD-10 Finland
Ventricular tachycardia
+∞
23.4
22
*
Z45.0
ICD-10 Finland
Adjustment and management of cardiac devices
258.0
23.1
23
*
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
258.0
23.1
23
*
351
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
+∞
22.3
21
*
FN1AC
NOMESCO Finland
Angiography of heart and/or coronary arteries
5.8
21.9
72
177
K78
ICPC
Atrial fibrillation/flutter
30.9
20.6
27
10
289
Kela drug reimbursment
Combination product containing sacubitril and valsartan
+∞
20.1
19
*
C09DX04
ATC
valsartan and sacubitril; oral
+∞
20.1
19
*
C09AA05
ATC
ramipril; oral
4.5
19.4
85
280
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
5.9
19.4
60
135
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
8.1
19.1
45
69
C01BD01
ATC
amiodarone; systemic
208.5
18.9
19
*
TFP20
NOMESCO Finland
Cardiodefibrillation
73.5
18.1
20
*
FM1DE
NOMESCO Finland
Doppler ultrasound examination of heart
9.9
17.1
35
42
I34.09
ICD-10 Finland
Mitral (valve) insufficiency
+∞
15.8
15
*
XF400
NOMESCO Finland
ECG with 12 standard connections
4.8
15.8
58
155
381
Kela drug reimbursment
Combination product containing sacubitril and valsartan
+∞
14.8
14
*
K70.0
ICD-10 Finland
Alcoholic fatty liver
24.5
14.5
20
9
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.9
14.3
50
126
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
12.2
13.4
24
22
I44.7
ICD-10 Finland
Left bundle-branch block, unspecified
+∞
12.6
12
*
I35.1
ICD-10 Finland
Aortic (valve) insufficiency
138.1
12.6
13
*
GD1LA
NOMESCO Finland
GD
138.1
12.6
13
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
9.2
12.5
26
32
F10.40
ICD-10 Finland
Withdrawal symptoms and delirium caused by alcohol without seizures
24.6
11.8
16
7
AN1
HP
Coronary angiography
4.7
11.1
39
97
P15
ICPC
Chronic alcohol abuse
11.5
10.5
19
18
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
115.7
10.5
11
*
PH1AC
NOMESCO Finland
Flebography of over extremity with X-ray
115.7
10.5
11
*
N07BB01
ATC
disulfiram; oral
7.3
9.8
23
35
F10.31
ICD-10 Finland
Withdrawal symptoms caused by alcohol with seizures
18.6
9.5
14
8
A12BA01
ATC
potassium chloride; oral
10.3
9.5
18
19
I46.0
ICD-10 Finland
Cardiac arrest with successful resuscitation
+∞
9.4
9
*
4273A
ICD-9 Finland
Cardiac dysrhythmias, Atrial fibrillation and flutter
+∞
9.4
9
*
FPG96
NOMESCO Finland
Other implantation of permanent cardioverter-defibrillator
+∞
9.4
9
*
A98
ICPC
Health maint/preventive medicine
0.4
9.2
124
1634
K77
ICPC
Heart failure
38.5
9.1
11
*
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
14.9
8.8
14
10
F10.2
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Dependence syndrome
14.9
8.8
14
10
R56.8
ICD-10 Finland
Other and unspecified convulsions
7.0
8.7
21
33
F10.20
ICD-10 Finland
Alcohol dependence currently independent
12.3
8.7
15
13
I34.00
ICD-10 Finland
Mitral (valve) incompetence NOS or of specified cause, except rheumatic
+∞
8.4
8
*
FPE20
NOMESCO Finland
Implantation of transvenous cardiac pacemaker with atrial and ventricular electrodes
+∞
8.4
8
*
FPG32
NOMESCO Finland
Implantation of cardioverter-defibrillator with atrial and ventricular electrodes
+∞
8.4
8
*
I42.2
ICD-10 Finland
Other hypertrophic cardiomyopathy
+∞
8.4
8
*
FPE96
NOMESCO Finland
Other implantation or replacement of transvenous cardiac pacemaker
+∞
8.4
8
*
4258A
ICD-9 Finland
Cardiomyopathy in other diseases classified elsewhere
+∞
8.4
8
*
I48.1
ICD-10 Finland
Persistent atrial fibrillation
+∞
8.4
8
*
F10.00
ICD-10 Finland
Alcohol-related acute intoxication uncomplicated
12.4
8.2
14
12
F10.21
ICD-10 Finland
Alcohol dependence currently abstinent, but staying in restrictive environment
23.1
8.1
11
5
TPH07
NOMESCO Finland
Cathetrisation of artery
4.3
8.1
30
79
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
8.1
64
295
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
9.0
8.0
16
19
F10.25
ICD-10 Finland
Alcohol dependence continuous use
10.0
7.9
15
16
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.4
7.8
90
509
F10.24
ICD-10 Finland
Alcohol depence active use
12.5
7.7
13
11
ZX120
NOMESCO Finland
Intravenous
4.2
7.5
28
74
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.2
7.5
41
148
C07AB02
ATC
metoprolol; systemic
2.9
7.4
49
202
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
11.5
7.4
13
12
I48.9
ICD-10 Finland
Atrial fibrillation and atrial flutter, unspecified
+∞
7.3
7
*
1CX08
NOMESCO Finland
NA
+∞
7.3
7
*
I42.8
ICD-10 Finland
Other cardiomyopathies
+∞
7.3
7
*
N05CF01
ATC
zopiclone; oral
2.4
7.2
75
396
115
Kela drug reimbursment
Breast cancer
5.3
7.2
21
43
I47.1
ICD-10 Finland
Supraventricular tachycardia
31.2
7.2
9
*
C07AA07
ATC
sotalol; systemic
10.6
7.1
13
13
F10.09
ICD-10 Finland
Alcohol intoxication UNS
10.6
7.1
13
13
F10.0
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Acute intoxication
10.6
7.1
13
13
XF404
NOMESCO Finland
Ambulatory ECG
6.3
7.1
18
31
B01AF02
ATC
apixaban; oral
8.0
7.0
15
20
F10.39
ICD-10 Finland
Withdrawal symptoms caused by alcohol UNS
14.4
7.0
11
8
N05BA02
ATC
chlordiazepoxide; systemic
8.7
6.9
14
17
PJD52
NOMESCO Finland
Block dissection of axillary lymph nodes
7.6
6.8
15
21
XFE00
NOMESCO Finland
Epicardial ultrasonography
23.4
6.7
9
*
M04AA01
ATC
allopurinol; systemic
3.2
6.7
37
134
L03AA02
ATC
filgrastim; parenteral
6.6
6.6
16
26
N05BA04
ATC
oxazepam; oral
2.6
6.6
54
250
R06.0
ICD-10 Finland
Dyspnoea
2.6
6.5
51
231
T36
ICD-10 Finland
Poisoning by systemic antibiotics
6.3
6.4
16
27
XF640
NOMESCO Finland
NA
11.5
6.4
11
10
2000B
ICD-9 Finland
Lymphosarcoma and reticulosarcoma, Reticulosarcoma[LYMPHOMA MALIGNUM DIFFUSUM]
+∞
6.3
6
*
TFP30
NOMESCO Finland
Cathetric examination for cardiac arrythmia
+∞
6.3
6
*
I42.1
ICD-10 Finland
Obstructive hypertrophic cardiomyopathy
+∞
6.3
6
*
I44.2
ICD-10 Finland
Atrioventricular block, complete
+∞
6.3
6
*
FPJ24
NOMESCO Finland
Revision of biventricular cardioverter-defibrillator with atrial and ventricular electrodes
+∞
6.3
6
*
42792
ICD-8 Finland
Symptomatic heart disease, Fibrillatio auricularis
+∞
6.3
6
*
K70.4
ICD-10 Finland
Alcoholic hepatic failure
27.6
6.3
8
*
I50
ICD-10 Finland
Heart failure
27.6
6.3
8
*
WX892
NOMESCO Finland
Monitored bed care
4.5
6.2
21
51
N05AA02
ATC
levomepromazine; systemic
4.9
6.2
19
42
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
59
178
4.14
17.80
7.9
4.5
1.1
1.0
mmol/l
0.82
54
166
34
97
3.95
10.81
3.3
2.1
8.4
4.7
ug/l
0.50
34
89
44
151
3.38
10.65
17.6
6.5
1.5
1.1
mmol/l
0.30
39
117
124
1693
0.40
10.03
4.8
4.4
4.6
4.7
mmol/l
0.52
109
1554
129
1728
0.40
9.79
5.5
4.9
2.7
2.8
mmol/l
0.82
115
1577
123
1680
0.41
9.78
4.8
4.4
1.3
1.4
mmol/l
1.71
108
1527
39
133
3.34
9.49
8.4
2.9
2.4
1.7
mmol/l
0.54
31
101
16
29
5.86
8.63
1.3
1.3
—
—
—
0
0
16
29
5.86
8.63
1.3
1.3
—
—
—
0
0
29
87
3.68
8.55
24.7
8.1
93.2
94.2
%
0.35
29
87
28
86
3.58
7.96
25.4
8.1
0.6
0.7
%
1.12
28
86
30
98
3.38
7.77
1.8
1.4
—
—
—
0
0
70
361
2.37
7.65
2.8
1.8
2.7
3.0
mg/l
0.63
61
309
27
86
3.43
7.26
25.8
8.0
1.7
1.5
%
0.52
27
86
52
938
0.42
7.08
3.9
4.9
1.9
2.7
ug/l
0.83
42
838
124
1627
0.47
7.08
4.7
3.9
1.6
1.3
mmol/l
3.33
109
1473
39
158
2.78
6.98
15.2
5.1
238.6
249.3
u/l
0.23
39
149
40
172
2.61
6.37
2.0
1.7
—
—
—
0
0
40
172
2.61
6.37
1.9
1.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
15
34
4.66
6.34
5.1
2.6
0.3
0.3
u/ml
—
9
15
125
1613
0.49
6.23
6.5
5.8
43.2
40.1
mmol/mol
1.99
112
1484
133
1675
0.49
6.00
5.2
4.5
6.5
6.0
mmol/l
1.98
120
1519
35
149
2.60
5.67
3.3
2.5
32.7
30.0
u/l
0.20
30
127
49
245
2.28
5.60
2.4
1.7
—
—
—
0
0
20
62
3.44
5.60
8.9
2.2
1.5
1.2
%
0.57
20
62
47
231
2.31
5.59
5.1
2.0
30.8
29.2
s
1.21
47
226
31
127
2.67
5.41
23.3
7.2
125.5
122.2
g/l
0.35
31
122
41
753
0.44
5.38
3.2
4.3
21.5
21.5
%
0.00
15
386
133
1640
0.53
4.80
33.4
11.8
79.6
80.2
ml/min/173m2
0.11
123
1332
89
597
1.81
4.36
3.8
2.3
197.3
187.9
ug/l
0.10
82
549
14
41
3.58
4.26
1.4
1.4
—
—
—
0
0
74
472
1.85
4.25
3.2
2.9
0.7
0.6
e6/l
0.20
62
341
15
47
3.35
4.14
5.4
5.2
2.2
1.3
mmol/l
0.66
15
47
35
173
2.21
4.07
3.8
3.4
16.4
9.1
umol/l
0.46
28
156
13
38
3.57
3.96
6.1
4.3
4.2
3.8
mmol/l
2.43
13
38
23
95
2.58
3.95
1.4
1.3
—
—
—
0
0
142
1680
0.58
3.66
36.1
12.3
28.9
25.2
mg/l
0.74
133
1296
31
553
0.49
3.43
2.4
3.0
0.6
0.8
ug/l
0.93
22
375
7
10
7.18
3.39
1.4
1.9
241.1
428.8
u/l
—
7
10
87
615
1.68
3.37
3.7
3.0
—
—
—
0
0
11
34
3.35
3.10
1.5
1.3
—
—
—
0
0
70
478
1.68
3.04
3.1
2.0
181.6
186.0
u/l
0.06
70
450
47
288
1.80
2.98
3.1
2.8
1.1
1.2
e6/l
0.02
32
167
68
935
0.61
2.92
2.9
2.7
—
—
—
0
0
57
376
1.69
2.79
4.1
2.2
—
—
—
0
0
9
25
3.71
2.60
1.2
1.2
—
—
—
0
0
12
44
2.83
2.59
1.4
1.1
—
—
—
0
0
129
1515
0.65
2.52
39.9
13.4
39.3
40.0
%
0.64
93
1074
7
16
4.48
2.49
1.3
1.4
—
—
—
0
0
101
783
1.53
2.49
15.9
5.9
1.2
1.2
mmol/l
3.07
85
670
9
27
3.43
2.42
2.1
1.7
—
—
—
0
0
9
27
3.43
2.42
1.9
1.7
—
—
—
0
0
6
12
5.10
2.41
2.5
1.8
—
—
—
0
0
69
495
1.57
2.39
3.5
3.6
48.1
30.8
u/l
1.79
64
479
8
23
3.57
2.29
1.1
1.3
—
—
—
0
0
7
18
3.98
2.27
2.1
1.9
—
—
—
0
0
48
324
1.61
2.13
8.8
1.8
2.3
1.4
mg/l
0.53
36
261
8
25
3.28
2.11
1.3
1.1
278.9
312.1
u/ml
—
8
15
5
10
5.09
2.08
1.8
1.4
15.6
13.4
umol/l
—
5
10
5
10
5.09
2.08
2.6
1.6
—
—
—
0
0
5
10
5.09
2.08
2.6
1.6
—
—
—
0
0
5
10
5.09
2.08
2.6
1.6
—
—
—
0
0
127
1472
0.68
2.06
4.8
4.0
2.0
1.9
mu/l
0.34
118
1295
8
28
2.92
1.88
1.0
1.4
—
—
—
0
0
114
955
1.39
1.68
12.7
9.6
4.5
4.1
e9/l
0.84
102
839
6
19
3.21
1.67
1.0
1.3
—
—
—
0
0
17
93
1.90
1.56
1.9
1.6
—
—
—
0
0
0
44
0.00
1.53
0.0
2.3
—
—
—
0
0
6
21
2.91
1.51
3.5
3.2
—
—
—
0
0
48
636
0.69
1.49
5.1
3.4
—
—
—
0
0
23
141
1.70
1.48
2.6
2.2
425.6
359.4
nmol/l
1.38
23
131
9
38
2.42
1.47
1.0
1.6
—
—
—
0
0
6
22
2.77
1.44
1.0
1.4
—
—
—
0
0
39
278
1.49
1.37
3.3
3.0
1.8
1.4
e6/l
0.11
23
160
5
17
2.98
1.36
1.4
1.2
—
—
—
0
0
0
38
0.00
1.35
0.0
1.3
—
2.7
—
0
7
66
813
0.73
1.30
4.3
3.2
0.0
0.0
estimate
0.00
13
135
99
1147
0.75
1.27
4.1
3.3
14.9
14.8
pmol/l
0.19
94
998
41
301
1.44
1.25
4.6
3.0
2.5
2.4
mmol/l
0.33
35
266
11
57
1.98
1.19
1.5
2.7
—
—
—
0
0
66
804
0.75
1.19
4.3
3.2
0.0
0.0
estimate
0.00
13
142
0
34
0.00
1.17
0.0
1.4
—
—
—
0
0
0
36
0.00
1.15
0.0
1.1
—
—
—
0
0
0
36
0.00
1.15
0.0
1.3
—
—
—
0
0
66
799
0.75
1.13
5.6
4.5
0.0
0.0
estimate
0.00
13
144
12
66
1.86
1.11
3.4
3.7
4.3
4.9
pmol/l
0.91
12
52
109
1229
0.78
1.06
4.5
3.8
19.8
12.0
mm/h
2.94
103
1121
5
22
2.30
1.04
2.4
1.3
103.8
77.6
pmol/l
—
5
22
64
523
1.31
1.02
5.6
3.5
2.3
2.3
mmol/l
0.75
56
456
5
23
2.20
0.98
1.2
1.3
17.6
16.7
ug/l
—
5
23
7
37
1.92
0.95
1.9
1.6
—
—
—
0
0
72
613
1.26
0.83
6.1
2.6
36.1
44.6
ng/l
0.37
61
428
10
60
1.70
0.73
1.3
3.1
—
—
—
0
0
15
216
0.67
0.73
19.7
5.5
—
—
—
0
0
7
39
1.82
0.73
1.0
1.4
—
—
—
0
0
5
25
2.02
0.73
1.0
1.0
—
—
—
0
0
16
224
0.69
0.68
1.5
1.5
—
—
—
0
0
10
62
1.64
0.66
3.6
1.8
—
—
—
0
0
5
29
1.74
0.64
1.0
1.0
—
—
—
0
0
12
174
0.67
0.62
2.7
2.1
7.4
13.9
nmol/l
2.10
12
157
23
175
1.35
0.61
5.5
2.8
—
—
—
0
0
0
20
0.00
0.60
0.0
1.0
—
511.7
—
0
10
0
20
0.00
0.60
0.0
1.1
—
37.1
—
0
10
0
23
0.00
0.58
0.0
1.4
—
—
—
0
0
6
37
1.64
0.56
1.8
2.7
—
—
—
0
0
36
432
0.80
0.55
5.4
3.3
0.0
0.0
estimate
0.50
12
140
15
108
1.42
0.54
5.3
2.7
53.4
68.0
ml/min/173m2
—
5
43
104
956
1.16
0.51
13.9
3.9
6.9
6.8
mmol/l
0.32
99
885
7
45
1.57
0.49
1.0
1.2
—
—
—
0
0
13
94
1.41
0.47
4.1
2.3
5.0
5.0
kpa
0.03
13
87
83
755
1.16
0.46
5.9
3.8
—
—
—
0
0
5
31
1.63
0.43
1.8
2.7
—
—
—
0
0
8
56
1.44
0.43
2.6
1.7
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
135
1278
1.14
0.41
14.9
7.8
87.8
79.9
u/l
0.97
130
1190
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
8
61
1.32
0.40
4.8
2.3
24.1
24.5
mmol/l
—
8
56
35
307
1.17
0.31
2.2
1.7
1204.0
1125.8
nmol/l
0.13
27
221
74
689
1.11
0.28
2.1
2.0
83.6
94.7
pmol/l
1.27
45
362
5
73
0.68
0.26
4.4
3.6
185.3
423.4
u/ml
—
5
63
33
370
0.87
0.26
1.9
1.7
455.3
18874598.2
pmol/l
0.50
23
302
5
38
1.32
0.23
1.6
1.7
—
—
—
0
0
104
1088
0.92
0.23
4.7
3.1
105.4
55.4
u/l
2.85
97
1015
5
41
1.22
0.22
1.0
1.0
—
0.7
—
0
5
8
104
0.76
0.21
3.4
1.9
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
5
43
1.17
0.21
1.2
1.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
9
111
0.80
0.20
3.2
2.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
6
53
1.14
0.19
1.5
1.2
—
—
—
0
0
6
53
1.14
0.19
1.5
1.2
—
—
—
0
0
14
121
1.17
0.15
4.4
4.0
1.2
1.2
mmol/l
1.97
14
111
22
243
0.90
0.14
1.0
1.2
17.6
40.6
iu/ml
—
6
77
11
119
0.92
0.04
1.5
1.4
—
—
—
0
0
65
638
1.03
0.03
2.7
2.2
71.9
76.6
nmol/l
0.57
59
560
24
237
1.01
0.00
1.0
1.2
1.1
13.2
u/ml
—
7
90
7
73
0.96
0.00
1.4
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1549.8
—
0
5
0
5
0.00
0.00
0.0
6.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
1346.8
—
0
6
0
5
0.00
0.00
0.0
1.4
—
109.2
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
55.3
—
0
7
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint I9_CARDMSEC and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CARDMSEC | 6.432 [4.18, 9.9] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.206 |
During the follow-up period (1.1.1998 — 31.12.2019), 110 out of 233 females with I9_CARDMSEC died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| I9_CARDMSEC | 7.233 [5.83, 8.98] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 480 out of 782 males with I9_CARDMSEC died.
Mortality risk
Mortality risk for people of age
years, who have I9_CARDMSEC.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.612% | 1.675% |
| 5 | 3.985% | 8.275% |
| 10 | 9.404% | 18.906% |
| 15 | 17.163% | 33.051% |
| 20 | 27.778% | 49.542% |
Relationships between endpoints
↥Index endpoint: I9_CARDMSEC – Cardiomyopathies, Secondary/extrinsic
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data